top of page
vaxa_logo_FF0000_transparent.png
LET'S TALK

— The Work Spans

Industries, geographies, and stages.

TECHNOLOGY

  • Fortune 50 enterprise software companies

  • Semiconductors and AI

  • Consumer electronics companies

  • Enterprise storage and infrastructure

Life Sciences & Health

  • Global medical device manufacturers

  • Medical wearable device companies

  • European theranostics, imaging startups

  • Global biotechnology companies

Industrials, Consumer & Public

  • Fortune 50 consumer packaged goods

  • Global automotive manufacturers

  • European telecommunications companies

  • US federal government agencies

GENOMICS & LIFE SCIENCES

DIGITAL HIGHWAY DISPLAYS

PLASTICS & ABSORBENTS IP

AED CATEGORY

NUTRACEUTICALS

CLIMATE

ADVANCED SCIENCES

DISASTER MANAGEMENT

SMART GLASS

DISRUPTIVE GROWTH

ibm ls small ChatGPT Image Jun 10, 2026, 01_21_05 AM.png

FEATURED

Technology · Life Sciences

Fortune 500 technology company

The market was questioning the future of this storied technology company  — and a life sciences market no one had properly sized.

$100 million committed to the life sciences opportunity within six months. A channel ecosystem built from scratch. A corporate venture capital program established that became one of the most significant in enterprise technology.

READ

Client Results

Every engagement on this page started with a conversation, not a brief.

If you're facing something similar — or something we haven't seen before — that's equally a reason to talk.

Stay ahead of what's forming. Subscribe to Vaxa Insights — our look at the critical issues and emerging opportunities facing businesses today.

Client confidentiality is non-negotiable. Names, engagement details, and outcomes are not shared without explicit permission. What is shown here reflects the character and scale of the work — not the full scope of it.

— CLIENT OUTCOMES

A market entry built on what you have — and designed for what you don't.

01

Clarity on which assets actually travel

A structured, honest assessment of which existing capabilities, relationships, technologies, and channels are genuinely deployable in the new market — and which only appear to be. Most organizations overestimate both. This assessment changes the entry design before capital is committed.

Entry designed on actual transferable assets, not assumed ones

02

A gap-filling strategy that uses the right mechanism

What cannot be transferred must be partnered, built, or acquired. Vaxa determines which mechanism is right for each gap — and in what order. The wrong mechanism for the wrong gap at the wrong time is the second most common failure point in new market entry.

Each gap addressed through the right partner, build, or acquisition path

03

A phased entry with defined triggers

New market entry that tries to do everything at once rarely survives first contact. Vaxa designs the phases — what moves first, what follows, and what the commercial and competitive triggers are before each step is taken. The entry is a sequence, not a single bet.

Entry sequenced in phases with clear triggers between each

04

The first customers before the entry scales

The specific organizations most likely to convert first, the commercial model that makes the first transaction possible, and the approach to reach them before the broader entry begins. Early customers in a new market are not a scale problem — they are a design problem.

First customer pipeline defined and sequenced before execution starts

client-results-hero-bg.png

—  CLIENT RESULTS

We don't just find markets.
We help build them.

At Vaxa, we have a passion for seeing things differently — for sensing what's forming before it's visible to anyone else. We work with clients who share that instinct, and together we turn what others overlook into markets, categories, and top-line growth that didn't exist before.

nokia-communications-card.png
microsoft small ChatGPT Image Jun 10, 2026, 10_36_57 AM.png

Technology · Enterprise Software

Fortune 500 enterprise software company

A new application portfolio — and no channel strategy to bring it to market.

Complete channel strategy, partner program, and ecosystem built to the architecture Vaxa designed.

nokia small ChatGPT Image Jun 10, 2026, 10_50_03 AM.png

telecommunicationS

European telecommunication company

They were asking the wrong question. It took three weeks to convince them.

A reframed question that opened a broader and more consequential addressable opportunity.

pg small ChatGPT Image Jun 10, 2026, 10_59_08 AM.png

CONSUMER GOODS · INNOVATION

F100 consumer packaged goods company

An innovation process that wasn't producing commercial outcomes — and dormant IP no one had thought to monetize.

New integrated innovation process. Plastics and absorbent IP monetized across four industries.

pg small ChatGPT Image Jun 10, 2026, 10_59_08 AM.png

CONSUMER GOODS · INNOVATION

F100 consumer packaged goods company

An innovation process that wasn't producing commercial outcomes — and dormant IP no one had thought to monetize.

New integrated innovation process. Plastics and absorbent IP monetized across four industries.

pg small ChatGPT Image Jun 10, 2026, 10_59_08 AM.png

CONSUMER GOODS · INNOVATION

F100 consumer packaged goods company

An innovation process that wasn't producing commercial outcomes — and dormant IP no one had thought to monetize.

New integrated innovation process. Plastics and absorbent IP monetized across four industries.

pg small ChatGPT Image Jun 10, 2026, 10_59_08 AM.png

CONSUMER GOODS · INNOVATION

F100 consumer packaged goods company

An innovation process that wasn't producing commercial outcomes — and dormant IP no one had thought to monetize.

New integrated innovation process. Plastics and absorbent IP monetized across four industries.

bottom of page